Meta-analysis of Efficacy and Safety of Endostar Combined with Gemcitabine and Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer
- VernacularTitle:重组人血管内皮抑制素联合吉西他滨、顺铂治疗非小细胞肺癌有效性与安全性的Meta分析
- Author:
Zhiqiang CHEN
1
;
Zeyun LI
1
;
Ruiting LIN
1
;
Weipeng SUN
1
;
Lizhu LIN
2
;
Lingling SUN
2
Author Information
1. First College of Clinical Medicine，Guangzhou University of TCM，Guangzhou 510405，China
2. Dept. of Oncology，the First Affiliated Hospital of Gua ngzhou U niversity of TCM，Guangzhou 510405，China
- Publication Type:Journal Article
- Keywords:
Endostar;
Gemcitabine;
Cisplatin;
Non-small cell lung cancer;
Therapeutic efficacy;
Safety;
Meta-analysis
- From:
China Pharmacy
2019;30(14):1990-1996
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To systematically evaluate the efficacy and safety of Endostar combined with gemcitabine and cisplatin in the treatment of non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use. METHODS： Retrieved from Cochrane Library， PubMed， Embase， ClinicalTrials， CNKI， Wanfang and VIP database， randomized controlled trials （RCT） about Endostar combined with gemcitabine and cisplatin（trial group） vs. gemcitabine combined with cisplatin （control group） for NSCLC were collected. After literature screening， data extraction and quality evaluation with Cochrane 5.1.0 bias risk evaluation tool and Jadad scale， Meta-analysis was performed by using Rev Man 5.3 software. RESULTS： A total of 27 RCTs were included， involving 1 646 patients. Results of Meta-analysis showed that response rate [RR＝1.67， 95％CI（1.48，1.89），P＜0.000 01] and clinical benefit rate [RR＝1.26， 95％CI （1.20， 1.33），P＜0.000 01] of trial group were significantly higher than those of control group. There was no statistical significance in the incidence of leucopenia [RR＝0.98，95％CI（0.88， 1.11），P＝0.79]， thrombocytopenia [RR＝1.07， 95％CI（0.91， 1.26），P＝0.39] and gastrointestinal reaction [RR＝1.01， 95％CI（0.90， 1.14），P＝0.85] between 2 groups. CONCLUSIONS： Endostar combined with gemcitabine and cisplatin can improve therapeutic efficacy of NSCLC patients， without increasing the incidence of ADR.
